Does a selective muscarinic receptor (M3) antagonist enhance the efficacy through oral delivery in chronic obstructive pulmonary disease patients?

Author： Naruganahalli Krishna S  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.7, 2007-07, pp. : 1127-1130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease

By Matera Maria Gabriella   Rogliani Paola   Cazzola Mario  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 961-977

Informa Healthcare

Access to resources Recommend Favorite

Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder

By Chapple Christopher R  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1493-1500

Informa Healthcare

Access to resources Recommend Favorite

The (S)-(+)-enantiomer of dimethindene: a novel M 2 -selective muscarinic receptor antagonist

By Pfaff O.   Hildebrandt C.   Waelbroeck M.   Xue H.   Moser U.   Mutschler E.   Lambrecht G.  

European Journal of Pharmacology, Vol. 286, Iss. 3, 1995-11 ,pp. : 229-240

Elsevier

Access to resources Recommend Favorite

Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease

By Joos Guy F  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 257-264

Informa Healthcare

Access to resources Recommend Favorite

Management of Insomnia in Patients With Chronic Obstructive Pulmonary Disease

By George C.F.P.  

Drugs, Vol. 63, Iss. 4, 2003-01 ,pp. : 379-387

Adis International

Access to resources Recommend Favorite